168
Participants
Start Date
August 10, 2018
Primary Completion Date
February 16, 2022
Study Completion Date
April 30, 2027
FOLFIRINOX
"FOLFIRINOX is a combination of 4 chemotherapy agents that may help shrink your tumor before surgery~* 5-Fluorouracil (5-FU) - 400 mg/m2 on day one, followed by 1200 mg/m2 by continuous infusion for the subsequent 46-48 hours~* Oxaliplatin - 85 mg/m2 by intravenous infusion over 120 minutes on day 1 of each 14 day cycle~* Irinotecan - administered at a starting dose of 180 mg/m2 by intravenous infusion over 90 minutes on day 1 of each 14 day cycle~* Leucovorin - Administered at a starting dose of 400 mg/m2 over 2 hours on day 1 of each 14 day cycle"
Losartan
Losartan is a drug that is used to lower blood pressure
Nivolumab
Nivolumab is an antibody that may cause programmed cell death of cancer cells
SBRT
Radiation therapy is believed to increase the likelihood of response of immunotherapy
Surgery
definitive surgical resection
New York University Langone Medical Center, New York
Sibley Memorial Hospital, Washington D.C.
The Johns Hopkins Hospital, Baltimore
MD Anderson Cancer Center, Houston
University of Colorado Cancer Center, Aurora
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Brigham and Women's Hospital, Boston
Dana Farber Cancer Institute, Boston
Newton Wellesley Hospital, Newton
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Stand Up To Cancer
OTHER
Lustgarten Foundation
OTHER
Massachusetts General Hospital
OTHER